Clinical Trials Search Results
Results 1-10 of 122 for your search
Show Search Criteria
Your Search Criteria
Category |
Your Selection |
|---|---|
| Keywords/Phrases: | "endometrial cancer" |
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 1188 locations
Age: 18 years and over
Gender: Male or Female
Location: 1188 locations
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 854 locations
Age: 18 years and over
Gender: Male or Female
Location: 854 locations
Tazemetostat in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer
Status: Active
Age: 18 years and over
Gender: Female
Location: 290 locations
Age: 18 years and over
Gender: Female
Location: 290 locations
Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer
Status: Active
Age: Not specified
Gender: Female
Location: 310 locations
Age: Not specified
Gender: Female
Location: 310 locations
Cabozantinib S-malate and Nivolumab in Treating Patients with Advanced, Recurrent or Metastatic Endometrial Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 33 locations
Age: 18 years and over
Gender: Male or Female
Location: 33 locations
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 29 locations
Age: 18 years and over
Gender: Male or Female
Location: 29 locations
Neratinib HER Mutation Basket Study (SUMMIT)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 18 locations
Age: 18 years and over
Gender: Male or Female
Location: 18 locations
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 20 locations
Age: 18 years and over
Gender: Male or Female
Location: 20 locations
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 14 locations
Age: 18 years and over
Gender: Male or Female
Location: 14 locations